Results 31 to 40 of about 164,596 (212)
Nature Communications, 2023 Cisplatin resistance along with chemotherapy-induced neuropathic pain is an important cause of treatment failure for many cancer types and represents an unmet clinical need.
Se Jin Oh +15 more
doaj +1 more source
Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]
, 2009 Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
B Stordal +7 more
core +2 more sources
Metabolic vulnerability of cisplatin‐resistant cancers [PDF]
The EMBO Journal, 2018 Cisplatin is the most widely used chemotherapeutic agent, and resistance of neoplastic cells against this cytoxicant poses a major problem in clinical oncology. Here, we explored potential metabolic vulnerabilities of cisplatin-resistant non-small human cell lung cancer and ovarian cancer cell lines.
Florine Obrist +11 more
openaire +2 more sources
Thoracic Cancer, 2021 Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in ...
Minghui Liu +8 more
doaj +1 more source
Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin [PDF]
, 2018 Cisplatin and derivatives are commonly used as chemotherapeutic agents. Although the cytotoxic action of cisplatin on cancer cells is very efficient, clinical oncologists need to deal with two major difficulties, namely the onset of resistance to the ...
Boxem, Mike +12 more
core +1 more source
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Molecular Cancer, 2022 Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhen-duo Shi +18 more
doaj +1 more source
Pulling a MAST1 on Cisplatin Resistance [PDF]
Cancer Cell, 2018 In this issue of Cancer Cell, Jin and colleagues use a kinome-wide screen to identify MAST1 as a cause of cisplatin resistance. They demonstrate that this kinase is a novel activator of MEK1 and the MAPK cascade and that it can harness pathway output to block cisplatin-induced cell death.
Ankita B, Jaykumar +2 more
openaire +2 more sources
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]
, 2007 We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross +2 more
core +1 more source
Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates [PDF]
, 2017 We present the anticancer properties of cis, cis, trans-[Pt(IV)(NH3)2Cl2(OA)2] [Pt(IV)diOA] (OA = octanoato), Pt(IV) derivative of cisplatin containing two OA units appended to the axial positions of a six-coordinate Pt(IV) center.
Brabec, Viktor +8 more
core +1 more source
RAB8 Enhances TMEM205-Mediated Cisplatin Resistance [PDF]
Pharmaceutical Research, 2011 To determine whether the small endosomal recycling GTPase, RAB8, plays a role in TMEM205-associated resistance to the chemotherapeutic drug cisplatin.Antibodies were used as markers for both genes; confocal microscopy was used to visualize their localization in cisplatin-resistant cells.
Ding-Wu, Shen, Michael M, Gottesman
openaire +2 more sources